๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Regulatory oversight of cellular therapies

โœ Scribed by A. Farrugia

Book ID
111414073
Publisher
Blackwell Publishing
Year
2007
Weight
228 KB
Volume
2
Category
Article
ISSN
1751-2816

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Regulatory issues in cellular therapies
Regulatory issues in cellular therapies
โœ Adrian P. Gee ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB

Cellular and gene therapies offer considerable promise as new treatment modalities. The Food and Drug Administration has been developing strategies to regulate these rapidly evolving fields in a manner that sustains progress and also ensures minimization of potential risks. The death of a patient on

Imaging of cellular therapies
Imaging of cellular therapies
โœ M. Srinivas; E.H.J.G. Aarntzen; J.W.M. Bulte; W.J. Oyen; A. Heerschap; I.J.M. de ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 497 KB
Regulatory oversight and automated tradi
Regulatory oversight and automated trading design: Elements of consideration
โœ Andrea M. Corcoran; John C. Lawton ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 675 KB

In 1992, the Chicago Mercantile Exchange (CME) and the Chicago Board of Trade (CBOT) launched the Globex system (V: 2, OOO) and CBOT also began trading through the Project A system. The New York Mercantile Exchange expects to launch its NYMEX ACCESS system in 1993. The views expressed herein are sol